Precision Biologics Secures USPTO Patent for NEO-201 Targeting Treg Cells
Precision Biologics Announces the United States Patent and Trademark Office (USPTO) has granted a Patent for its Lead Monoclonal...
Precision Biologics Secures USPTO Patent for NEO-201 Targeting Treg Cells
Patent rights jointly owned by the National Cancer Center and the University of Pennsylvania, licensed to ARC Therapies, Inc.
For healthy adults, taking multivitamins daily is not associated with a lower risk of death
Kate, Princess of Wales, makes first public appearance since cancer diagnosis
Analysis-Before global scrutiny, Indian spice maker MDH faced many US rejections
Smiling King Charles visits cancer centre on his return to public duties
Factbox-The health of Britain's King Charles: sporting accidents to cancer diagnosis